CASE-BASED PITFALLS AND LIMITATIONS OF PIRADS v2.0
|
|
- Mercy Chase
- 5 years ago
- Views:
Transcription
1 CASE-BASED PITFALLS AND LIMITATIONS OF PIRADS v2.0 Antonio Luna, MD, PhD. Medical Director. Health Time. Jaén, Spain. Assistant professor of radiology. Case Western Reserve University. Cleveland, OH. Scientific director of the Spanish Society of Radiology (SERAM)
2 DISCLOSURES Consultant for Bracco Imaging (Milan, Italy) and sporadically Lecturer for GE and Toshiba in the last year. Royalties from Springer for several book publications
3 TEACHING POINTS To highlight the limitations of PIRADS version 2 in the characterization of significant prostate cancer using a case-based approach To identify false positive and negative lesions in significant cancer detection using PIRADS version 2 To review common and uncommon MRI pitfalls and tricks for significant prostate cancer detection
4 Introduction Multiparametric MRI (mpmri) has a growing impact in prostate cancer (PCa) management, being considered the most accurate imaging technique for its detection and localization, due to its ability to detect clinically significant tumors (Gleason score > 7) Recently, European Guidelines of EAU has included mp-mri as an option after a first negative transrectal-ultrasound guided biopsy (TRUS) in patients with clinical suspicion of PCa. In addition, the PIRADS v2 standard from ACR and ESUR helps to improve the reproducibility in the reading of mpmri between different centers and radiologist. Mottet N et al. EAU Prostate Cancer Guidelines 2015 Weinreb JC et al. PIRADS v
5 Introduction However, this reading system is far from being perfect, with limitations related to: o Decreased sensitivity due to false negatives cases, as there are some clinical significant PCa, which are not detectable with MRI. o Decreased specificity, as some normal anatomical structures and benign pathologies may simulate malignant disease. Mottet N et al. EAU Prostate Cancer Guidelines 2015 Weinreb JC et al. PIRADS v
6 Introduction Multiparametric MRI (mpmri) has a growing impact in prostate cancer (PCa) management, being considered the most accurate imaging technique for its detection and localization, due to its ability to detect clinically significant tumors (Gleason score > 7) Recently, European Guidelines of EAU has included mp-mri as an option after a first negative transrectalultrasound guided biopsy (TRUS) in patients with clinical suspicion of PCa. In addition, the PIRADS v2 standard from ACR and ESUR helps to improve the reproducibility in the reading of mpmri between different centers and radiologist. However, this reading system is far from being perfect, with limitations related to: o Decreased sensitivity due to false negatives cases, as there are some clinical significant PCa, which are not detectable with MRI. o Decreased specificity, as some normal anatomical structures and benign pathologies may simulate malignant disease. This review deals with the more common limitations and pitfalls of PIRADS v2 guidelines, in an intend to help radiologists to recognize these potential pitfalls. Mottet N et al. EAU Prostate Cancer Guidelines 2015 Weinreb JC et al. PIRADS v
7 Case 1: rule out significant prostate cancer DWI DCE-MRI There are 3 PCa in the prostatectomy specimen: PCa Gleason 3+4 in posterolateral right PZ, which is a PIRADS 5 lesion on MRI (red circle) PCa Gleason 3+3 in posterolateral left PZ, which is a bandlike hypointense lesion on, not clearly visible in the rest of sequences, consistent with PIRADS 2 lesion. PCa Gleason 3+3 in anterior transitional zone, which retrospectively is only seen as a tiny hypointense nodule on, without any associated abnormality in the rest of sequences (PIRADS 1).
8 PCa detection with mpmri Now PCa is considered a multifocal disease, with one index lesion and one or more additional distant secondary low-grade, low-volume lesions. This heterogeneity has limited current diagnostic pathway, as it cannot differentiate between both types of disease, leading to: o Overdiagnosis and overtreatment of low grade PCa o Underdiagnosis and undertreatment of high grade Pca Prostatectomy specimen showing multifocal PCa MRI has been introduced in the diagnostic armamentarium of PCa, as it is the most accurate imaging technique for its detection and localization, due to its outstanding ability to detect clinically significant tumors (Gleason score > 7) Ahmed, H. The Lancet Oncology, 2012; 13(11), e509 e517. Weinreb JC et al. PIRADS v
9 Case 2: 70 year-old male. PSA: 5.3 ng/ml
10 False negative lesions PCa 3+4 PCa 4+3 False negative PCa Gleason 4+3 on DWI. On right PZ, there is a band-like hypointense area on, which is not clearly visible in the rest of sequences. Prostatectomy specimen demostrates a PCa Gleason 4+3 (thunder). Asterisk represent a PCa Gleason 3+4 in anterior fibromuscular stroma not depicted on MRI images.
11 Case 3: 58 year-old male. PSA: 3.9 ng/ml DWI
12 Case 3: 58 year-old male. PSA: 3.9 ng/ml Substraction DCE-MRI Wash-in map DWI PIRADS 2 lesion: ill-defined area on WI no abnormality on and high b value DWI focal area of enhancement on left PZ (curve type 3) Gleason score (3+4) in 10% of a 1 cm core Incidental area of hemorrhage in posterolateral right PZ (arrowheads)
13 False negative lesions Low volume or small significant tumor On mpmri, tumors smaller than 0.5 cm are considered not visible. Also, it is assumed that most of the Gleason 6 tumors are not depicted with mpmri. But over this size, there are others factors that influence detection: o According to recent data, among tumor foci containing Gleason pattern 4, the only independent predictors of tumor detection were accordingly increasing tumor size and non-cribriform predominant architecture The definition of clinical significant cancer is still under debate, as: o some groups consider it any tumor with Gleason score > 7, o others separate Gleason 3+4 from Gleason over 4+3 in different prognostic groups, o others take into account the proportion of tumor burden in the biopsy cores or the proportion of Gleason 4 pattern
14 Case 4: 80 year-old male. PSA: 8.26 ng/ml DWI b 1400 * On right PZ, PIRADS 3 lesion: focal hypointense abnormality with low signal intensity on WI hypointense nodule on map not detectable on b 1400 s/mm 2 image. On targeted biopsy, a PCa Gleason 3+4 with 37% of involvement of the cores is confirmed. Lack of visibility on high b value image can be related to diffuse inflammatory changes in the rest of PZ, as it can be seen in the left posterolateral PZ on WI (asterisk)
15 Case 5: 21 year-old male with pelvic pain. PIRADS 2 lesion large well-defined mass of intermediate signal intensity on WI, which invades all the TZ. severe restriction of DWI heterogeneous peripheral enhancement, with central areas of lack of enhancement representing necrosis. b1000 DCE-MRI
16 False negative lesions Other tumors than adenocarcinoma b1000 DCE-MRI Undifferentiated sarcoma with miliary pulmonary metastases at diagnosis.
17 False negative lesions Other tumors than adenocarcinoma Sarcomas of the prostate o are rare tumours, accounting for % of all primary prostatic neoplasms. o are predominantly mesenchymal in origin but, they may also arise from stromal components o on the -weighted sequences, prostate sarcomas invariably appear as heterogeneous masses with areas of intermediate and high signal. Necrosis and cystic change in these tumours is common, because of their high malignancy and rapid growth o may demonstrate a well-defined low signal compressible pseudocapsule o usually show restriction on DWI and avid enhancement reflecting its aggressive nature
18 False negative lesions Other tumors than adenocarcinoma Rastinehard AR et al. Biomedical Data Mining 2015, 3:2 Non acinar subtypes of adenocarcinoma and sarcomas are more difficult to detect with mpmri if following strictly PIRADS v2 standard Ductal adenocarcinoma is the most common variant of nonacinar PCa (0.5-6% of all PCa). This is a very aggressive variant which behaves differently on mpmri: o Usually shows high signal intensity on WI, with similar appearance to Gleason score 6 tumors o shows restriciton of DWI and increased perfusion on DCE-MRI
19 Case 6: 49 year-old male with persistent hematuria and normal PSA level. DWI DCE PIRADS 2 lesion very large encapsulated nodule is depicted in the middle lobe, homogeneous low signal intensity on WI, restriction of diffusion and type II TIC.
20 False positive lesions : Giant Stromal BPH nodule DWI DCE 49 year-old male with persistent hematuria and normal PSA level. A very large encapsulated nodule is depicted in the middle lobe, which shows homogeneous low signal intensity on WI, restriction of diffusion and type II TIC. On targeted biopsy, a stromal BPH is demonstrated.
21 False positive lesions : Stromal BPH nodule BPH typically enlarges TZ due to hyperplasia of both the prostatic stromal and epithelial cells. BPH shows a multinodular configuration of TZ. Hyperintense nodules on WI represents hyperplastic glandular elements, which are easily differentiated from PCa with MRI Stromal and mixed nodules are most commonly hypointense on WI, and, in addition, they show restriction of water diffusion and early enhancement on DCE-MRI. Morphological criteria based on WI are the best to differentiate between stromal nodular hyperplasia and PCa of the TZ, although DWI can also help as PCa usually show a greater proportion of restriction Rarely, stromal BPH nodule can be detected in the PZ mimicking PCa.
22 False positive lesions : Stromal BPH nodule b2000 DCE-MRI MRI shows 2 stromal BPH nodules in left TZ. Both are well-defined, encapsulated, - hypointense nodules, with avid and fast enhancement and delayed washout (type 3 TIC). Both of them, also demonstrate restriction of diffusion, being more evident in the one located anteriorly. Both are PIRADS 2 lesions according to their benign appearance on WIs
23 Case 7: 63 year-old male. PSA: 6.4 ng/ml 3+3 Acute prostatitis DWI DCE PIRADS 5 lesion located on right PZ Nodular lesion, with moderate hypointense signal on WI and, marked restriction of diffusion and severe asymmetrical enhancement
24 Common in urology clinics Local (+) systemic symptomps Imaging does not form part of its normal work-up More likely in young men Caused by intraprostatic urine reflux or after prostate biopsy Histology: influx of neutrophils MRI: similar apperance to chronic prostatitis and overlaps with PCa May cause intraprostatic abscess and pelvic lymph node enlargement False positive lesions Acute prostatitis 3+3 Acute prostatitis Nodular lesion, with moderate hypo signal on WI and located on right PZ, shows marked restriction of diffusion and severe asymmetrical enhancement. It was classified as PIRADS 5. Prostatectomy specimen showed acute prostatitis. In addition, an incidental PCa Gleason 6 (3+3) was identified on anterior TZ, not detectable on MRI. DWI DCE
25 Case 8: 63 year-old male. PSA 7.2 ng/ml. DRE (+) On left PZ, PIRADS 5 lesion Markedy hypointense nodule on WI, restriction of diffusion peripheral enhancement central area of low intensity signal on all the sequences DWI DCE Acute purulent prostatitis with caseous necrosis in the prostatectomy specimen.
26 False positive lesions Acute prostatitis/abscess ababds DWI A large prostatic abscess is shown in the anterior TZ. Typical findings on MRI are demonstrates such as restriction of diffusion, peripheral enhancement and hyperintense content on TWI. This is a probably benign lesion (PIRADS 2)according to PIRADS v2 guidelines. uncommon condition, often difficult to discern clinically from acute prostatitis. focal accumulation of pus within the prostate gland. the common infecting organisms are Neisseria gonorrheae, Staphylococcus aureus and Mycobacterium tuberculosis, and also gram negative bacteria, such as Escherichia coli mainly affects diabetic and immunosuppressed patients. percutaneous transperineal or transrectal drainage under transrectal sonography is the first choice for therapy DCE
27 Case 9: 72 year-old male. PSA: 5.6 ng/ml DWI PIRADS 4 in the lateral right PZ a focal round nodule on WI (< 1.5 cm), high signal intensity on high b value DWI and low signal on.
28 False positive lesions: Chronic prostatitis Prostatitis almost always originates in the PZ often associated with elevated PSA levels, sometimes showing fluctuation, raising the suspicion of PCa. decrease of PSA with antibiotherapy favors the diagnosis Caused by undertreated acute prostatitis and recurrent infection or if lower tract infection is present. Clinically indolent. Urine culture (-) Histologically, chronic prostatitis is characterized by extracellular edema surrounding the involved prostatic cells with lymphocytes, plasma cells, macrophages, and neutrophils in the prostatic stroma. This abundance in cells as compared with normal prostatic tissue lead to an decrease. In this manner, chronic prostatitis is a common cause of false positive in targeted biopsies using areas of low as reference to define targets DWI PIRADS 4 in the lateral right PZ a focal round nodule on WI (< 1.5 cm), high signal intensity on high b value DWI and low signal on. This is biopsy proven chronic prostatitis which MRI findings cannot be differentiated from those of significant PCa.
29 MR appearance False positive lesions Acute and chronic prostatitis WI Acute prostatits Midly hypointense area with ill-defined margins May be diffuse Chronic prostatitis Ill-defined or lineal low signal intensity area in the PZ A lobar or diffuse distribution ispossible In the TZ is uncommon, but can mimic the erased charcoal sign of PCa High b value Mild to moderate hyperintense Mild to moderate hyperintensity Mild to moderate hypointense Mild to moderate hypointensity DCE-MRI Very intense and fast early enhancement, that can be diffuse and involving a greater area than the - abnormality Abscess may be a complication Acute prostatits Pitfall Similar to chronic prostatitis, may appear similar to PCa Usually even more intense enhancement than chronic prostatitis Intense and early enhancement Association to atrophy and scar Chronic prostatitis Great mimicker of significant PCa that usually shows bordeline pathological PIRADS scores Morphological criteria helps to their differentiation but they can be very similar Overlap also in their appearance in functional sequences with PCa, although chronic prostatitis usually show less restriction of diffusion than PCa. In this setting, quantification of has been proposed, as chronic prostatitis is expected to show higher values than significant PCa Trick Clinical history may help PCa is more well-defined and nodular in appearance
30 Case 10: 59 year-old male. PSA: 3.5 ng/ml DCE PIRADS 2 lesion Band-like hypointense area on axial WI with associated loss of volume. mild lineal areas of high signal intensity on DWI and low signal on corresponding map. intense and asymmetric enhancement. DWI
31 False positive lesions Glandular atrophy/postinflammatory scars DCE Band-like hypointense area on axial WI with associated loss of volume. It shows mild lineal areas of high signal intensity on DWI and low signal on corresponding map. The lesion shows intense and asymmetric enhancement. As it is not focal, suggests a PIRADS 2 abnormality, which corresponds to an area of focal atrophy of inflammatory origin. MR appearance DWI WI Focal or geographical area of low signal intesity High b value Moderately hyperintense Moderately hypointense DCE-MRI Moderate enhancement Pitfall Trick Nodule with imaging characteristics than overlap PCa in PZ Less restriction of diffusion and enhancement than significant PCa Volume loss may be associated
32 False positive lesions Postinflammatory scars DWI DCE TARGETED BIOPSY A 63 year-old male with PSA: 4 ng/ml and previous negative biopsy 5 months before. A triangular-shaped hypointense focal area of 7 mm is depicted on WI at right basal PZ, which also shows a linear area of restriction of diffusion and early enhancement. A targeted MRI/US fusion biopsy demonstrates a focal area of fibrosis at this level.
33 False positive lesions Glandular atrophy/postinflammatory scars Atrophy is a frequent finding at prostate biopsy, not mentioned by pathologist very commonly o Histologically shows crowded glands with scant cytoplasm and crowding of nuclei o Caused by inflammation, radiation, antiandrogens and chronic ischemia o Types: simple, sclerotic with cyst formation and post-atrophic hyperplastic o Direct relationship between its extent and the total or free serum elevation of PSA Postinflammatory scars usually occurs after prostatitis, and are located in the PZ Both are mimickers of PCa, and their MRI findings overlap those of chronic prostatitis
34 Case 11: 56 year-old male. PSA: 5.32 ng/ml DWI DCE Targeted biopsy: Gleason 3+4
35 Case 11: 66 year-old male with antecedent of recurrent bladder carcinoma. Persistent and progressive elevation of PSA. 4 negative previous TRUS-Bx DWI DCE On left PZ, PIRADS 3 lesion Markedy hypointense nodule on WI Midly hypointense nodule on Not detectable on DWI Perfusion (-) Granulomatous prostatitis in a patient with previous BCG injections
36 False positive lesions Granulomatous prostatitis Uncommon benign inflammatory condition Clinically is similar to PCa (firm nodule + PSA elevation) Types: o Idiopathic: more frequent, non specific and non necrotic. o Infectious: specific, non necrotic or necrotic. After intravesical bacille Calmette-Guérin (BCG) therapy or tuberculous prostatitis o Iatrogenic: postsurgical (TURP or bladder surgery) o Malacoplakia: rare granulomatous disease. Similar to PCa in MRI. o Associated with systemic granulomatous disease (sarcoidosis): rare Incidental finding in MRI for rectal cancer staging. Previous intravesical Bacille Calmette-Guérin therapy for bladder cancer. MRI depicts the presence of bladder polyps (arrowheads) on WI. MRI also shows a focal hypointense area of 17 mm on left peripheral zone on WI (arrows,) which also shows low signal intensity on map suspicious for prostate cancer. This corresponds to a PIRADS 5 lesion, confirmed as non necrotic granulomatous prostatitis
37 MR appearance WI False positive lesions Granulomatous prostatitis Non necrotic granulomatous prostatits Very hypointense discrete mass with illdefined margins and nodular to bandlike shape Necrotic granulomatous prostatits High signal intensity High b value Hyperintense Hyperintense Markedly hypointense Markedly hypointense DCE-MRI Intense enhancement Large areas of lack on enhancement= caseous necrosis, Moderate surrounding enhancement Pitfall Trick Non necrotic granulomatous prostatits Nodular lesion with similar imaging characteristics to PCa. May show extraprostatic extension Clinical history may help Only specific diagnosis is histological analysis Necrotic granulomatous prostatits Restriction of diffusion Residual patchy areas of markedly low signal intensity due to calcification fibrosis and noncaseating necrosis Areas of caseous necrosis Incidental finding in MRI for rectal cancer staging. Previous intravesical Bacille Calmette-Guérin therapy for bladder cancer. MRI depicts the presence of bladder polyps (arrowheads) on WI. MRI also shows a focal hypointense area of 17 mm on left peripheral zone on WI (arrows,) which also shows low signal intensity on map suspicious for prostate cancer. This corresponds to a PIRADS 5 lesion, posteriorly confirmed as non necrotic granulomatous prostatitis
38 False positive lesions: Pitfalls related to anatomic structures Normal anatomic structures can show a bizarre configuration and simulate PCa in mpmri Radiologist should recognize the various presentations of these normal prostatic structures Anatomic structures that may simulate PCa 1. Anterior fibromuscular stroma 2. Central zone 3. Surgical capsule 4. Periprostatic veins 5. Neurovascular bundles
39 Located in the most anterosuperior part of the prostate gland Composed of fibrous and smooth muscular elements o Absence of glandular tissue o Apical half is rich in striated muscle and blends into the gland and the muscle of the pelvic diaphragm o laterally and posteriorly, it thins to form the fibrous capsule that surrounds the prostate gland MR appearance Pitfalls related to anatomic structures Anterior fibromuscular stroma WI Marked and homogeneous hypointensity Symmetric configuration High b value Isointense b1000 b2000 DCE-MRI DCE-MRI Iso- to hypointense Absence of early enhancement Progressive enhancement (type I TIC) Normal anterior fibromuscular stroma in a 43 year-old male without signs of BPH. Anterior fibromuscular stroma is markedly hypointense on WIs, shows absence of restriction and slow and progressive enhancement on DCE-MRI.
40 Case 12: 76 year-old male with persistent and progressive elevation of PSA (PSA=5ng/mL). DWI b2000 DCE- MRI PIRADS 5 lesion in right anterior fibromuscular stroma ill-defined nodule, hypointense on WI mild restriction of diffusion enhancement (+)
41 Pitfalls related to anatomic structures Anterior fibromuscular stroma DWI b2000 Feb/2016 DWI b2000 Targeted MR/US fusion biopsy was negative for malignancy, consistent with asymmetric hyperthrophy of the anterior fibromuscular stroma Jul/2017 Pitfall Trick asymmetrical hyperthophy may show a nodular or lenticular appearance and look like PCa absence of restriction diffusion or significant early enhancement
42 Case 13: 59 year-old male. PSA: 28 ng/ml DWI b1400 DCE Targeted MR/US fusion biopsy showed a Gleason 4+4 PCa
43 Pitfalls related to anatomic structures Anterior fibromuscular stroma Pca b year-old male with PSA= 8.42 ng/ml. Systematic TRUS biopsy showed a PCa Gleason 3+3 en in right lobe in only 1 fragment with involvement of 15%. Posteriorly, MRI is performed demonstrating a highly suspicious lesion (PIRADS 5) in anterior fibromuscular stroma. Targeted biopsy revealed a PCa Gleason 8 (4+4). * b year-old male with increasing PSA up to 23.4 ng/ml. A lentiform hypointense lesion on WIs is depicted, with origin in the inferior aspect of the anterior fibromuscular stroma (asterisk), and with invasion of apical anterior TZ. The lesion shows aggressivenes both in morphological and functional sequences. Targeted MR/US fusion biopsy confirmed a PCa Gleason 4+3. DCE-MRI
44 Case 14: 62 year-old male. PSA:5.6 ng/ml DWI
45 MR appearance WI Pitfalls related to anatomic structures Central zone Its embryologic origin is from the Wolffian duct, different than the rest of the prostate gland (urogenital sinus) Represent aproximately 25% of the total prostatic volume Reduce its size in the presence of BPH, with poorer depiction on MRI Symmetric band between the PZ and TZ at the base, from below the SV to the verumontanum and surrounding the ejaculatory ducts High b value DCE-MRI Hypointense Moustache sign at the base of the prostate: Median posterior zone in the middle third of the gland Hyperintense Hypointense Progressive enhancement (type I TIC) or progressive enhancement + plateau (type 2 TIC) Uncommonly, washout (type 3 TIC) Pitfall Trick Moustache appearance of normal central zone symmetrical oval shape, sharp margins homogeneous dark signal intensity on WI asymmetrical hyperthrophy may show a nodular or lenticular appearance and look like PCa easy to recognize on coronal WI as: reversed tear drop appearance
46 Case 15: 69 year-old male. PSA: 4.6. Free/Total PSA ratio: 14%. DWI b2000 DCE-MRI On left central zone, PIRADS 5 lesion A hypointense asymmetrical nodule is identified on -weighted images with invasion of seminal vesicles restricition of diffusion and Perfusion (+), type II TIC.
47 Pitfalls related to anatomic structures Prostate cancer of the central zone Targeted MR/TRUS fusion biopsy demonstrates a Gleason 8 (4+4) PCa < 5% of PCa are located in the central zone, but are typically more aggressive Low sensitivities, but with high specificities have been reported for detection of PCa of the central zone with MRI
48 Case 16: 58 year-old male. PSA: 3.8 ng/ml. b2000 DCE-MRI On paramedian right PZ, hypointense nodule on axial TSE WI hypointense on. Absence of high signal on DWI and a tubular shape on coronal TSE-WI sugggest this is a pseudolesion, MIP of the venous phase of the DCE-MRI confirms a vascular structure at this level.
49 Located around the lateral margins of the prostate gland, closely to the prostate capsule Communicates with a plexus anterior to the prostate Pitfalls related to anatomic structures Periprostatic venous plexus b2000 MR appearance WI High b value Hypointense signal may be present Isointense DCE-MRI Hypointense DCE-MRI Early and persistent enhancement Pitfall Trick May simulate a low signal nodule on WI in the apical PZ No high signal on DWI MIP of venous enhanced series easily demonstrates the enhancing tubular vascular structure Axial TSE WI demonstrates a hypointense nodule (arrow) of paramedian right PZ, which is also hypointense on. Absence of high signal on DWI and a tubular shape on coronal TSE-WI sugggest this is a pseudolesion, as confirmed in the MIP of the venous phase of the DCE-MRI, where a vascular structure can be identified at this level.
50 Located in the posterolateral aspect of the prostate Composed of loose connective and adipose tissue containing the periprostatic venous plexus intermixed with arteries, nerves, and lymphatics Sometimes, the nerve trunks are sparsed around the lateral aspect of the prostate, without a true NV bundle are critical to mantain normal erectile function Through the NV bundles: cavernous neural plexus innervates the corpora cavernosa the prostate gland receives both parasympathetic and sympathetic innervation MR appearance Pitfalls related to anatomic structures Neurovascular bundles DCE-MRI b2000 WI High b value DCE-MRI Pitfall Trick Hypointense Isointense Signal void Progressive and predominant delayed enahncement may show a nodular appearance when viewed on face on axial plane Tubular structure on the posterolateral margin of the PZ 63 year-old male with PSA level=5 ng/ml and free to total PSA ratio=12% and 2 previous negative biopsies. A hypointense nodule is demonstrated on axial WI, which presents a band-like hypointense appearance on map, and nodular enhancement on DCE- MRI. On high b value, it is mininally hyperitense. This corresponds to a PIRADS 4 lesion, but coronal WI confirms it truly represents the right NV close to the prostatic margin.
51 Located in the posterolateral aspect of the prostate Composed of loose connective and adipose tissue containing the periprostatic venous plexus intermixed with arteries, nerves, and lymphatics Sometimes, the nerve trunks are sparsed around the lateral aspect of the prostate, without a true NV bundle are critical to mantain normal erectile function Through the NV bundles: cavernous neural plexus innervates the corpora cavernosa the prostate gland receives both parasympathetic and sympathetic innervation MR appearance Pitfalls related to anatomic structures Neurovascular bundles DCE-MRI b2000 WI High b value DCE-MRI Pitfall Trick Hypointense Isointense Signal void Progressive and predominant delayed enahncement may show a nodular appearance when viewed on face on axial plane Tubular structure on the posterolateral margin of the PZ 63 year-old male with PSA level=5 ng/ml and free to total PSA ratio=12% and 2 previous negative biopsies. A hypointense nodule is demonstrated on axial WI, which presents a band-like hypointense appearance on map, and nodular enhancement on DCE- MRI. On high b value, it is mininally hyperitense. This corresponds to a PIRADS 4 lesion, but coronal WI confirms it truly represents the right NV close to the prostatic margin.
52 Acknowledgements LIMITATIONS OF PIRADS v2 Antonio Luna MD, PhD. Health Time, Jaén. Spain. Case Medical Center. Case Western Reserve University. Cleveland, OH. Lidia Alcalá-Mata, MD. Health Time, Jaén. Spain Teodoro Martin-Noguerol, MD. Health Time, Jaén. Spain Roberto Garcia Figueiras MD; PhD. Complexo Hospitalario Santiago de Compostela, Spain. Joan C. Vilanova MD, PhD. IDI. Clinica Girona. Girona, Spain. Mariano Volpacchio, MD. Centr Diagnostico Rossi. Buenos Aires, Argentina. Violeta Catalá, MD.Fundació Puigvert. Autonoma University. Barcelona, Spain,
Prostate MRI. Overview. Introduction 2/20/2015. Prostate cancer is most frequently diagnosed noncutaneous cancer in males (25%)
Prostate MRI John Bell, MD Introduction Prostate Cancer Screening Staging Anatomy Prostate MRI overview Functional MRI Multiparametric Approach Indications Example Cases Overview Introduction Prostate
More informationProstate Cancer Imaging: most common pitfalls in multiparametric Magnetic Resonance
Prostate Cancer Imaging: most common pitfalls in multiparametric Magnetic Resonance Poster No.: C-0698 Congress: ECR 2017 Type: Educational Exhibit Authors: L. Basso, M. Baglietto, S. Migone, V. Prono,
More informationLocalized at a focus, central point or locus. Localized finding distinct from neighboring tissues, not a threedimensional
LEXICON ABNORMALITY Focal abnormality Focus Index Lesion Lesion Localized at a focus, central point or locus Localized finding distinct from neighboring tissues, not a threedimensional space occupying
More information11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015.
Multi-parametric MRI of Prostate Diagnosis and Treatment Planning Temel Tirkes, M.D. Associate Professor of Radiology Director, Genitourinary Radiology Indiana University School of Medicine Department
More informationPI-RADS V2 IN PRACTICE A PICTORIAL REVIEW
PI-RADS V2 IN PRACTICE A PICTORIAL REVIEW KP Murphy, A Walsh, C Donagh, R Aljurayyan, AC Harris, SD Chang Department of Abdominal and GU Radiology, Vancouver General Hospital & University of British Columbia,
More informationProstate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
More informationEssentials of Clinical MR, 2 nd edition. 73. Urinary Bladder and Male Pelvis
73. Urinary Bladder and Male Pelvis Urinary bladder carcinoma is best locally staged with MRI. It is important however to note that a thickened wall (> 5 mm) is a non-specific finding seen in an underfilled
More information1 Uniform hyperintense signal intensity (normal). 2 Linear (arrow), wedge-shaped, or diffuse mild hypointensity, usually indistinct margin.
Figure 3 PI-RADS assessment for peripheral zone on T2-weighted imaging. 1 Uniform hyperintense signal intensity (normal). 2 Linear (arrow), wedge-shaped, or diffuse mild hypointensity, usually indistinct
More informationCase Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.
Case Scenario 1 3/8/13 H&P 68 YR W/M presents w/elevated PSA. Patient is a non-smoker, current alcohol use. Physical Exam: On digital rectal exam the sphincter tone is normal and there is a 1 cm nodule
More informationProstate Cancer DFP Case of the Week
Prostate Cancer DFP Case of the Week Antonio C. Westphalen, MD PhD Clinical Prostate MR Imaging Program, Director Associate Professor of Radiology and Urology University of California, San Francisco Case
More informationMRI and Fusion biopsies. K Sahadevan Consultant Urologist
MRI and Fusion biopsies K Sahadevan Consultant Urologist MRI in Prostate Cancer Diagnosis Traditionally used for staging purposes 70 to 90% accurate detection of extra capsular disease on MRI (cornud 2002)
More informationMultiparametric Prostate MRI: PI-RADS V.2
Multiparametric Prostate MRI: PI-RADS V.2 Katarzyna J. Macura, MD, PhD, FACR, FSCBTMR The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD SCBT
More informationPSA. HMCK, p63, Racemase. HMCK, p63, Racemase
Case 1 67 year old male presented with gross hematuria H/o acute prostatitis & BPH Urethroscopy: small, polypoid growth with a broad base emanating from the left side of the verumontanum Serum PSA :7 ng/ml
More informationBrief History. Identification : Past History : HTN without regular treatment.
Brief History Identification : Name : 陳 x - Admission : 94/10/06 Gender : male Age : 75 y/o Chief Complaint : Urinary difficulty for months. Past History : HTN without regular treatment. Brief History
More information3/28/2017. Disclosure of Relevant Financial Relationships. GU Evening Subspecialty Case Conference. Differential Diagnosis:
GU Evening Subspecialty Case Conference Rajal B. Shah, M.D. VP, Medical Director, Urologic Pathology Miraca Life Sciences, Irving, Texas Clinical Associate Professor of Pathology Baylor College of Medicine,
More informationProstate Cancer Imaging :What the Urologist Needs to Know
Prostate Cancer Imaging :What the Urologist Needs to Know Poster No.: C-2513 Congress: ECR 2015 Type: Educational Exhibit Authors: C. Aimeur, M. tabouche, A. habouchi, A. Habba, B. Mansouri; Algiers/DZ
More informationSome prostatic diseases
Some prostatic diseases Benign Prostatic Hyperplasia (Nodular Hyperplasia) Extremely common Present in a significant number of men by the age of 40 & its frequency rises progressively with age, reaching
More informationProstate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018
Prostate cancer staging and datasets: The Nitty-Gritty What determines our pathological reports? Dan Berney Maastricht 2018 Biopsy reporting. How not to do it. The TNM 8 th edition. Changes good and bad
More informationPROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging
PROSTATE MRI Dr. Margaret Gallegos Radiologist Santa Fe Imaging Topics of today s talk How does prostate MRI work? Definition of multiparametric (mp) MRI Anatomy of prostate gland and MRI imaging Role
More informationThey Do Look Alike : Mimics of Prostate Cancer in Biopsy Samples
They Do Look Alike : in Biopsy Samples Gladell P. Paner, MD Departments of Pathology and Surgery (Urology) University of Chicago, IL USA Gladell.paner@uchospitals.edu Benign in Needle Biopsy 1. Benign
More informationProblems: TRUS Bx. Clinical questions in PCa. Objectives. Jelle Barentsz. Prostate MR Center of Excellence.
Multi-parametric MR imaging in Problems: TRUS Bx Low Risk Prostate Cancer Important cancers are missed Jelle Barentsz Clinically insignificant cancers are identified by Prostate MR Center of Excellence
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationI have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation.
Prostate t Cancer MR Report Disclosure Information Vikas Kundra, M.D, Ph.D. I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a g product
More informationPI-RADS version 2 - what we need to know
PI-RADS version 2 - what we need to know Poster No.: C-1846 Congress: ECR 2017 Type: Educational Exhibit Authors: I. Abreu, D. Roriz, A. P. Pissarra, Â. Moreira, C. B. Marques, 1 1 2 1 1 1 1 2 F. Caseiro
More informationImproved Detection of Clinically Significant Prostate Cancer Using a Structured Prostate Imaging Reporting Data System (PI-RADS) Template
Improved Detection of Clinically Significant Prostate Cancer Using a Structured Prostate Imaging Reporting Data System (PI-RADS) Template Abstract #17-130 ACR Annual Meeting 2017 Presenting Author: Whitney
More informationOutline (1) Outline (2) Concepts in Prostate Pathology. Peculiarities of Prostate Cancer. Peculiarities of Prostate Cancer
Concepts in Prostate Pathology Murali Varma Cardiff, UK wptmv@cf.ac.uk Sarajevo Nov 2013 Outline (1) Peculiarities of prostate cancer Peculiarities of prostate needle biopsy Needle bx vs. TURP Prostate
More informationPitfalls in Interpreting mp-mri of the Prostate: A Pictorial Review with Pathologic Correlation
Insights Imaging (2015) 6:611 630 DOI 10.1007/s13244-015-0426-9 PICTORIAL REVIEW Pitfalls in Interpreting mp-mri of the Prostate: A Pictorial Review with Pathologic Correlation V. Panebianco 1 & F. Barchetti
More informationMRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know
MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know Michael S. Cookson, MD, FACS Professor and Chair Department of Urology Director of Prostate and Urologic Oncology University
More informationOptimizing Implementation of Prostate MRI. Andrei S Purysko, M.D. Section of Abdominal Imaging & Nuclear Radiology Department
Optimizing Implementation of Prostate MRI Andrei S Purysko, M.D. Section of Abdominal Imaging & Nuclear Radiology Department Objectives To review the basic components of a state-of-the-art mpmri of the
More informationThe Egyptian Journal of Hospital Medicine (April 2018) Vol. 71 (2), Page
The Egyptian Journal of Hospital Medicine (April 2018) Vol. 71 (2), Page 2490-2497 Role of ADC Map MR Imaging in Prediction of Local Aggressiveness of Prostate Cancer Asaad Gamal Asaad Sorial, Omar Farouk
More informationOASIS 1.2T: MULTIPARAMETRIC MRI OF PROSTATE CANCER
OASIS 1.2T: MULTIPARAMETRIC MRI OF PROSTATE CANCER By Dr. John Feller, MD, Radiologist Desert Medical Imaging, Palm Springs, CA MRI is clinically accepted as the best imaging modality for displaying anatomical
More informationINTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein
INTRADUCTAL LESIONS OF THE PROSTATE Jonathan I. Epstein Topics Prostatic intraepithelial neoplasia (PIN) Intraductal adenocarcinoma (IDC-P) Intraductal urothelial carcinoma Ductal adenocarcinoma High Prostatic
More informationMultiparametric MRI diagnostic value in a case of prostate cancer
CASE REPORT J. Transl. Med. Res 2015;20(3):162-167 Multiparametric MRI diagnostic value in a case of prostate cancer Gelu Adrian Popa 1,4, Ioana Gabriela Lupescu 1,4, Emi M. Preda 1,4, Cristina Nicolae
More informationHypoechoic Rim of Chronically Inflamed Prostate, as Seen at TRUS: Histopathologic Findings
Hypoechoic Rim of Chronically Inflamed Prostate, as Seen at TRUS: Histopathologic Findings Hak Jong Lee, MD 1 Ghee Young Choe, MD 2 Chang Gyu Seong, MD 3 Seung Hyup Kim, MD 4 Index terms: Prostate Prostate,
More informationDiseases of the breast (1 of 2)
Diseases of the breast (1 of 2) Introduction A histology introduction Normal ducts and lobules of the breast are lined by two layers of cells a layer of luminal cells overlying a second layer of myoepithelial
More informationStandards for MRI reporting the evolution to PI-RADS v 2.0
Review Article Standards for MRI reporting the evolution to PI-RADS v 2.0 Michael Spektor, Mahan Mathur, Jeffrey C. Weinreb Department of Radiology and Biomedical Imaging, Yale New Haven Hospital, USA
More informationMultiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer
Multiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer RadioGraphics 2018; 38:437 449 Pritesh Patel, MD Melvy S. Mathew, MD Igor Trilisky, MD Aytekin Oto, MD, MBA Jeffrey S. Klein,
More informationThe role of T2-weighted imaging in detecting prostate cancer of the central zone in 3T multiparametric magnetic resonance examination
The role of T2-weighted imaging in detecting prostate cancer of the central zone in 3T multiparametric magnetic resonance examination Poster No.: C-2317 Congress: ECR 2014 Type: Scientific Exhibit Authors:
More informationS1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles
Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Sex Male
More informationClinical Prostate Cancer Imaging
Clinical Prostate Cancer Imaging Steven C. Eberhardt, MD Professor and Vice Chair of Clinical Operations Chief of Abdominal and Oncology Radiology UNM Health Sciences Center UNM Comprehensive Cancer Center
More information3/23/2017. Significant Changes in Prostate Cancer Classification, Grading, Staging and Reporting. Disclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships Staging and Reporting of Prostate Cancer: Major Changes in 8 th Edition AJCC Staging and CAP Cancer Checklists USCAP requires that all planners (Education
More informationUpdate on Reporting Prostate Cancer Pathology
Update on Reporting Prostate Cancer Pathology Dr. Andrew J. Evans MD, PhD, FACP, FRCPC Consultant in Genitourinary Pathology University Health Network, Toronto, ON None Disclosures Learning Objectives
More informationKidney, Bladder and Prostate Neoplasia. David Bingham MD
Kidney, Bladder and Prostate Neoplasia David Bingham MD typical malignant cytology of bladder washings 1 benign 2 malignant typical malignant cytology of bladder washings b Bladder tumor Non invasive papillary
More informationGross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of
Tiền liệt tuyến Tiền liệt tuyến Gross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of solid and microcystic areas.
More informationDiagnosis, pathology and prognosis including variant pathology
PROSTATE CANCER Diagnosis, pathology and prognosis including variant pathology No Conflict of Interest Universitat Autónoma de Barcelona F.Algaba Section of Pathology PROSTATE CANCER Diagnosis, pathology
More informationPapillary Lesions of the Breast A Practical Approach to Diagnosis. (Arch Pathol Lab Med. 2016;140: ; doi: /arpa.
Papillary Lesions of the Breast A Practical Approach to Diagnosis (Arch Pathol Lab Med. 2016;140:1052 1059; doi: 10.5858/arpa.2016-0219-RA) Papillary lesions of the breast Span the spectrum of benign,
More informationImaging in breast cancer. Mammography and Ultrasound Donya Farrokh.MD Radiologist Mashhad University of Medical Since
Imaging in breast cancer Mammography and Ultrasound Donya Farrokh.MD Radiologist Mashhad University of Medical Since A mammogram report is a key component of the breast cancer diagnostic process. A mammogram
More informationProstate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144
Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Objectives: Detection of prostate cancer the need for better imaging What
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationEssential Initial Activities and Clinical Outcomes
Essential Initial Activities and Clinical Outcomes Crystal Farrell 1,2 & Sabrina L. Noyes 2, Joe Joslin 2, Manish Varma 2,3, Andrew Moriarity 2,3, Christopher Buchach 2,3, Leena Mammen 2,3, Brian R. Lane
More informationNeoplasia literally means "new growth.
NEOPLASIA Neoplasia literally means "new growth. A neoplasm, defined as "an abnormal mass of tissue the growth of which exceeds and is uncoordinated with that of the normal tissues and persists in the
More informationProstate biopsy: MR imaging to the rescue
Prostate biopsy: MR imaging to the rescue Poster No.: C-1855 Congress: ECR 2014 Type: Educational Exhibit Authors: N. V. V. B. Marques 1, J. Ip 1, A. Loureiro 2, J. Niza 1, M. Palmeiro 2, Keywords: DOI:
More informationAnatomic Imaging of Prostate Cancer
Masoom Haider, MD, FRCP(C) Professor of Radiology, University of Toronto Clinician Scientist, Ontario Institute of Cancer Research Senior Scientist, Sunnybrook Research Institute Chief, Dept of Medical
More informationProcedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy
Prostate Gland Protocol applies to invasive carcinomas of the prostate gland. Protocol web posting date: July 2006 Protocol effective date: April 2007 Based on AJCC/UICC TNM, 6 th edition Procedures Needle
More informationKidney Case 1 SURGICAL PATHOLOGY REPORT
Kidney Case 1 Surgical Pathology Report February 9, 2007 Clinical History: This 45 year old woman was found to have a left renal mass. CT urography with reconstruction revealed a 2 cm medial mass which
More informationARTHUR PURDY STOUT SOCIETY COMPANION MEETING: DIFFICULT NEW DIFFERENTIAL DIAGNOSES IN PROSTATE PATHOLOGY. Jonathan I. Epstein.
1 ARTHUR PURDY STOUT SOCIETY COMPANION MEETING: DIFFICULT NEW DIFFERENTIAL DIAGNOSES IN PROSTATE PATHOLOGY Jonathan I. Epstein Professor Pathology, Urology, Oncology The Reinhard Professor of Urological
More informationProstate Cancer Grading, Staging and Reporting: An Update Cristina Magi-Galluzzi, MD, PhD
Prostate Cancer Grading, Staging and Reporting: An Update Cristina Magi-Galluzzi, MD, PhD Director, Genitourinary Pathology R.J. Tomsich Pathology & Laboratory Medicine Institute Professor of Pathology,
More informationobjectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University
objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University To determine the regions of physiologic activity To understand
More informationInterac(ve Experience with Prostate Imaging Repor(ng and Data System Version 2 (PI-RADS v2)
Interac(ve Experience with Prostate Imaging Repor(ng and Data System Version 2 (PI-RADS v2) E Hassanzadeh 1,2, MD; E Velez 3, BS; F M Fennessy 1,4, MD, PhD; R M Dunne 1,2, MBBCh; M G Harisinghani 1,5,
More informationProstate Pathology: Prostate Carcinoma, variants and Gleason Grading (Part 1)
Prostate Pathology: Prostate Carcinoma, variants and Gleason Grading (Part 1) Jae Y. Ro, MD, PhD June 7, 2012 Ten Leading Cancer Types for the Estimated New Cancer Cases and Deaths By Sex, United States,
More informationArmed Forces Institute of Pathology.
Armed Forces Institute of Pathology www.radpath.com Armed Forces Institute of Pathology Breast Disease www.radpath.org Armed Forces Institute of Pathology Interpretation of Breast MRI Leonard M. Glassman
More informationProstate MRI based on PI-RADS version 2: how we review and report
Steiger and Thoeny Cancer Imaging (2016) 16:9 DOI 10.1186/s40644-016-0068-2 REVIEW Prostate MRI based on PI-RADS version 2: how we review and report Philipp Steiger 1,2* and Harriet C. Thoeny 1,2 Open
More informationProstate Cancer MRI. Accurate Diagnosis and Treatment. PSA to Prostate MRI. for patients and curious doctors
6 Prostate Cancer MRI Accurate Diagnosis and Treatment PSA to Prostate MRI for patients and curious doctors Samuel Aronson, M.D. Vincent Pelsser, M.D. Franck Bladou, M.D. Armen Aprikian, M.D. & Marc Emberton,
More informationS1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES
Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Indigenous
More informationMRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review
MRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review Poster No.: C-1208 Congress: ECR 2014 Type: Educational Exhibit Authors: J. Murphy, M.
More informationADENOCARCINOMA OF THE PROSTATE
Ref : ADENOCARCINOMA OF THE PROSTATE Div. of Urology, Dept. Surgery Medical Faculty, University of Sumatera Utara Clinical Manual of Urology, (Philip M. Hanno et al eds), McGraw-Hill Int ed, 3 rd ed, 2001
More informationCase #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).
SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More informationPathology of the Prostate. PathoBasic Tatjana Vlajnic
Pathology of the Prostate PathoBasic 24.01.17 Tatjana Vlajnic Overview Adenocarcinoma of the prostate Grading Special variants Mimickers of prostate adenocarcinoma Atrophy Inflammatory conditions Granulomatous
More informationDifferential Diagnosis of Oral Masses. Palatal Lesions
Differential Diagnosis of Oral Masses Palatal Lesions Palatal Masses Periapical Abscess Torus Palatinus Mucocele Lymphoid Hyperplasia Adenomatous Hyperplasia Benign Salivary Neoplasms Malignant Salivary
More informationMacro- and microacinar proliferations of the prostate
Macro- and microacinar proliferations of the prostate (with emphasis on cancer mimics) Rodolfo Montironi, MD (IT), FRCPath (UK), IFCAP (USA) Polytechnic University of Marche Region (Ancona) School of Medicine,
More informationImaging Ejaculatory Disorders and Hematospermia
ATHENS 4-6 October 2018 European Society of Urogenital Radiology Imaging Ejaculatory Disorders and Hematospermia Parvati Ramchandani, MD Professor, Radiology and Surgery University of Pennsylvania Medical
More information1. Benign Prostate Hyperplexia (BPH) 2. Prostate Cancer (PCa)
Objectives: Our first segment focused in the anatomy and functions of the prostate gland, to get a clear understanding of the male Genito-Urinary System. Now, we will explore two of the main problems associated
More informationACCME/Disclosures. Cribriform Lesions of the Prostate. Case
Cribriform Lesions of the Prostate Ming Zhou, MD, PhD Departments of Pathology and Urology New York University Langone Medical Center New York, NY Ming.Zhou@NYUMC.ORG ACCME/Disclosures The USCAP requires
More informationHHS Public Access Author manuscript Abdom Radiol (NY). Author manuscript; available in PMC 2017 January 19.
Prostate Imaging Reporting and Data System Version 2 (PI- RADS v2): A pictorial review Elmira Hassanzadeh, MD 1, Daniel I Glazer, MD 1, Ruth M Dunne, MD 1, Fiona M Fennessy, MD, PHD 2, Mukesh G Harisinghani,
More informationAims and objectives. Methods and materials. Background
Updated Prostate Imaging Reporting and Data System (PI-RADS) 2.0 versus 1.0: detection accuracy of prostate clinically significant and insignificant cancer Poster No.: C-1203 Congress: ECR 2016 Type: Scientific
More informationUtility of Prostate MRI. John R. Leyendecker, MD
Utility of Prostate MRI John R. Leyendecker, MD Professor of Radiology and Urology Executive Vice Chair of Clinical Operations Section Head, Abdominal Imaging Wake Forest University School of Medicine;
More informationMagnetic Resonance Imaging in the management of prostate cancer: What the Radiologists need to know?
Magnetic Resonance Imaging in the management of prostate cancer: What the Radiologists need to know? Poster No.: C-0889 Congress: ECR 2014 Type: Educational Exhibit Authors: S. S. Deshpande, N. Sable,
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationProstate Cancer. David Wilkinson MD Gulfshore Urology
Prostate Cancer David Wilkinson MD Gulfshore Urology What is the Prostate? Male Sexual Gland Adds nutrients and fluids for sperm This fluid is added to sperm during ejaculation Urethra (urine channel)
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationSalivary Glands 3/7/2017
Salivary Glands 3/7/2017 Goals and objectives Focus on the entities unique to H&N Common board type facts Information for your future practice Salivary Glands Salivary Glands Major gland. Paratid. Submandibular.
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationEssentials of Clinical MR, 2 nd edition. 65. Benign Hepatic Masses
65. Benign Hepatic Masses Pulse sequences acquired for abdominal MRI typically consist of fast acquisition schemes such as single-shot turbo spin echo (i.e. HASTE) and gradient echo schemes such as FLASH
More informationStephen McManus, MD David Levi, MD
Stephen McManus, MD David Levi, MD Prostate MRI Indications INITIAL DETECTION, STAGING, RECURRENT TUMOR LOCALIZATION, RADIATION THERAPY PLANNING INITIAL DETECTION Clinically suspected prostate cancer before
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More informationCTA/MRA of Pediatric Hepatic Masses Radiology-Pathology Correlation
Acta Radiológica Portuguesa, Vol.XVIII, nº70, pág. 41-50, Abr.-Jun., 2006 CTA/MRA of Pediatric Hepatic Masses Radiology-Pathology Correlation Marilyn J. Siegel Mallinckrodt Institute of Radiology, Washington
More informationMultiparametric 3T MR imaging of the prostate - acquisition protocols and image evaluation
Multiparametric 3T MR imaging of the prostate - acquisition protocols and image evaluation Poster No.: C-2215 Congress: ECR 2014 Type: Educational Exhibit Authors: L. Andrade, C. B. Marques, L. Curvo-Semedo,
More informationCase Scenario 1: Breast
Case Scenario 1: Breast A 63 year old white female presents with a large mass in her left breast. 4/15/13 Mammogram/US: 1. Left breast mammographic and sonographic at 3:00 measuring 7.1 cm highly suggestive
More informationCurrent Clinical Practice. MR Imaging Evaluations. MRI Anatomic Review. Imaging to Address Clinical Challenges. Prostate MR
BETH ISRAEL DEACONESS MEDICAL CENTER Prostate MR Neil M. Rofsky, MD Harvard Medical School Current Clinical Practice DIGITAL RECTAL EXAMINATION PSA ( ~ 20% False negative) BIOPSY (18-25% False negative)
More informationBoot Camp Case Scenarios
Boot Camp Case Scenarios Case Scenario 1 Patient is a 69-year-old white female. She presents with dyspnea on exertion, cough, and right rib pain. Patient is a smoker. 9/21/12 CT Chest FINDINGS: There is
More informationOptimal Imaging and Technical Aspects of Prostate SRT
Optimal Imaging and Technical Aspects of Prostate SRT Maris Mezeckis Dr., MBA, Vladislav Buryk Dr., PhD Sigulda Hospital Stereotactic Radiosurgery centre Homogeneous planning: PTV=prostate + 5 mm, 3 mm
More informationProstate Biopsy in 2017
Prostate Biopsy in 2017 Bob Djavan, MD, PhD Professor and Chairman, Department of Urology, Rudolfinerhaus Foundation Hospital,Vienna, Austria Director Vienna Urology foundation Board member Scientific
More informationBenign breast lesions frequently encountered on MR
Benign breast lesions frequently encountered on MR Poster No.: C-1385 Congress: ECR 2012 Type: Educational Exhibit Authors: J. R. Almeida 1, J. C. Marques 2 ; 1 Lisbon/PT, 2 lisbon/pt Keywords: Hemangioma,
More informationRENAL CELL CARCINOMA 2 to 3% of All New Visceral Cancers Peak Incidence is 6th Decade M:F = 2:1 Grossly is a Bright Yellow, Necrotic Mass with a Pseud
GENITOURINARY PATHOLOGY Kathleen M. O Toole Toole, M.D. RENAL CELL CARCINOMA 2 to 3% of All New Visceral Cancers Peak Incidence is 6th Decade M:F = 2:1 Grossly is a Bright Yellow, Necrotic Mass with a
More informationInteresting Cases from Liver Tumor Board. Jeffrey C. Weinreb, M.D.,FACR Yale University School of Medicine
Interesting Cases from Liver Tumor Board Jeffrey C. Weinreb, M.D.,FACR Yale University School of Medicine jeffrey.weinreb@yale.edu Common Liver Diseases Hemangioma Cyst FNH Focal Fat/Sparing THID Non-Cirrhotic
More information2 to 3% of All New Visceral Cancers Peak Incidence is 6th Decade M:F = 2:1 Grossly is a Bright Yellow, Necrotic Mass with a Pseudocapsule
GENITOURINARY PATHOLOGY Kathleen M. O Toole, M.D. Renal Cell Carcinoma 2 to 3% of All New Visceral Cancers Peak Incidence is 6th Decade M:F = 2:1 Grossly is a Bright Yellow Necrotic Mass Grossly is a Bright
More informationGleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA
Gleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA Learners Objectives u Latest changes per ISUP 2014 that impact
More information